New study in JNCCN unlocks important information about how to treat recurring prostate cancer
PLYMOUTH MEETING, PA [February 9, 2026] — New research in the February 2026 issue of JNCCN—Journal of the National Comprehensive Cancer Network found that incorporating information from prostate-specific membrane antigen (PSMA) PET/CT scans may be able to predict progression-free survival (PFS) and guide treatment planning in patients with rising prostate-specific antigen (PSA) levels following removal of the prostate.
The researchers used retrospective clinical data from 113 patients treated for prostate ...